GSBGEN Health Care Technology: From Innovators to Providers to Patients
Health Law: Health Care Providers
All Directions
Health Law
Health Care Providers
Health Law: Life Science Research Institutions & Companies
[ A ] [ L ] [ R ] [ T ]
Intellectual Property: Life Sciences/ Biotechnology
[ A ] [ L ] [ R ] [ T ]
Law School CoursesRelated Law Courses by TopicCourses Outside SLS by TopicClinic(s)ResourcesYour Network
272 items in this track |
205 / 272 Item is good for 19 routes, rollover orange dots above to see which ones! GSBGEN 351 Health Care Technology: From Innovators to Providers to Patients Graduate School of Business Recommended for route(s): [ Academia ] [ Litigation ] [ Regulatory & Policy ] [ Transactional ] Health Law: Health Care Providers Why it is relevant for ... [ Academia ] [ Litigation ] [ Regulatory & Policy ] [ Transactional ] as a Relevant Course outside SLS for those interested in Management : ++ { HIGHLY RELEVANT } ++ Innovation in the biomedical sciences is rapidly redefining health care. Diseases that were once considered terminal are now treatable, although they frequently require a long period of continuing care. This progress comes at a huge cost: health care expenses now account for almost 17% of the Gross Domestic Product (GDP) in the U.S., and they are expected to continue to grow rapidly. Managers in both the public and private sectors face mounting challenges posed by the number and complexity of treatments and diagnostics spurred by innovation. Healthcare providers must coordinate different healthcare functions and service providers in pursuit of a common goal of maximizing the value provided by health care. Students interested in the healthcare industry should consider taking 1 or more courses to gain a better understanding of current issues in healthcare management. The course below focuses on the effect of innovation on the integration of patient care and the generation of value. General course Description: This course examines health care businesses and how they use technology (primarily biotechnology, medical technology and information technology) to improve patient outcomes and manage costs. New technologies are commercialized by innovator companies (biotech and pharmaceutical companies, device manufacturers, diagnostics developers, and health IT companies). They are adopted by providers (hospitals, physicians) in patient care and paid for by third-party payers (commercial and government). We will use case studies to examine the following: For the innovators, a) financing and managing new product development b) clinical trial management and gaining regulatory approval, c) marketing, communication and sales strategies (both physician and patient communication and sales) to drive product adoption and gain third party reimbursement. d) Business models to drive innovation. For the providers, a) The clinical and business case for adopting a new technology b) The organizational changes new technology may necessitate especially when it generates new patient safety risks. For the payers, a) the process and criteria they use to make reimbursement and coverage decisions and how these criteria affect innovators, b) selective provider network design to manage the added costs of these new technologies, and c) new it-intensive business models. Through these case studies, the students will not only gain an in depth understanding of how new technologies get developed and commercialized in health care but how the whole health care value chain adapts to these new technologies. Interviews, panel discussions, and guest lecturers from prominent industry leaders will supplement the case discussions. Speakers and panelsts in previous years included senior executives from Genentech, Gilead, Onyx Pharmaceuticals, Medtronic, Jazz Pharmaceuticals, United Health, DaVita, and Genomic Health; venture investors from Essex Woodland Health Ventures and Prospect Ventures; and heads of the health care/biotech practices at McKinsey and Goldman Sachs. Course Style: A Substantive course teaches the law, theory, and policy in a particular area of law |
    |
